Interaction between sulthiame and clobazam: Sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19

Epilepsy and Behavior

Volumn 34, Issue , 2014, Pages 124-126

  Yamamoto, Yoshiaki ^a,b   Takahashi, Yukitoshi ^a   Imai, Katsumi ^a   Mogami, Yukiko ^a   Matsuda, Kazumi ^a   Nakai, Masahiko ^a   Kagawa, Yoshiyuki ^b,c   Inoue, Yushi ^a  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c SHIZUOKA GENERAL HOSPITAL   (Japan)

Author keywords

Clobazam; CYP2C19; Drug interaction; Sulthiame; Therapeutic drug monitoring

Indexed keywords

CLOBAZAM; CYTOCHROME P450 2C19; DRUG METABOLITE; ETIRACETAM; LAMOTRIGINE; N DESMETHYL CLOBAZAM; PHENYTOIN; PRANLUKAST; RISPERIDONE; SULTIAME; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; THIAZINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGGRESSION; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; EPILEPSY; FEMALE; FOCAL EPILEPSY; GENOTYPE; HUMAN; HUMAN TISSUE; INSOMNIA; IRRITABILITY; MALAISE; MALE; MUSCLE SPASM; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; DRUG INTERACTION; ENZYMOLOGY; METABOLISM;

ADULT; ANTICONVULSANTS; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2C19; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; THIAZINES;

EID: 84898871629     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.03.018     Document Type: Article

References (13)

1. Doose H., Baier W.K., Ernst J.P., Tuxhorn I., Völzke E. Benign partial epilepsy-treatment with sulthiame. Dev Med Child Neurol 1988, 30:683-684.
2. Swiderska N., Hawcutt D., Eaton V., Stockton F., Kumar R., Kneen R., et al. Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit. Seizure 2011, 20:805-808.
3. Wirrell E., Ho A.W., Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr Neurol 2006, 35:204-208.
4. Patsalos P.N. Sulthiame: antiepileptic drug interactions. A clinical guide 2013, 151-156. Springer, London. 2nd ed.
5. Hansen J.M., Kristensen M., Skovsted L. Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism. Epilepsia 1968, 9:17-22.
6. Houghton G.W., Richens A. Inhibition of phenytoin metabolism by sulthiame in epileptic patients. Br J Clin Pharmacol 1974, 1:59-66.
7. Houghton G.W., Richens A. Phenytoin intoxication induced by sulthiame in epileptic patients. J Neurol Neurosurg Psychiatry 1974, 37:275-281.
8. Giraud C., Tran A., Rey E., Vincent J., Tréluyer J.M., Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004, 32:1279-1286.
9. Chiron C., Marchand M.C., Tran A., Rey E., d'Athis P., Vincent J., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356:1638-1642.
10. Inoue Y., Ohtsuka Y., Oguni H., Tohyama J., Baba H., Fukushima K., et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009, 50:2362-2368.
11. Yamamoto Y., Takahashi Y., Imai K., Miyakawa K., Nishimura S., Kasai R., et al. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl-clobazam concentrations in patients with epilepsy. Ther Drug Monit 2013, 35:305-312.
12. Kinoshita M., Ikeda A., Begum T., Terada K., Shibasaki H. Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci 2007, 263:44-48.
13. Seo T., Nagata R., Ishitsu T., Murata T., Takaishi C., Hori M., et al. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics 2008, 9:527-537.